Literature DB >> 23836444

Cost of illness for neuromuscular diseases in the United States.

Jane Larkindale1, Wenya Yang, Paul F Hogan, Carol J Simon, Yiduo Zhang, Anjali Jain, Elizabeth M Habeeb-Louks, Annie Kennedy, Valerie A Cwik.   

Abstract

INTRODUCTION: We conducted a comprehensive study of the costs associated with amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD). and myotonic dystrophy (DM) in the U.S.
METHODS: We determined the total impact on the U.S. economy, including direct medical costs, nonmedical costs, and loss of income. Medical costs were calculated using a commercial insurance database and Medicare claims data. Nonmedical and indirect costs were determined through a survey of families registered with the Muscular Dystrophy Association.
RESULTS: Medical costs were driven by outpatient care. Nonmedical costs were driven by the necessity to move or adapt housing for the patient and paid caregiving. Loss of income correlated significantly with the amount of care needed by the patient.
CONCLUSIONS: We calculated the annual per-patient costs to be $63,693 for ALS, $50,952 for DMD, and $32,236 for DM. Population-wide national costs were $1,023 million (ALS), $787 million (DMD), and $448 million (DM).
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Duchenne Muscular Dystrophy; Myotonic Dystrophy; Neuromuscular diseases; amyotrophic lateral sclerosis; cost of illness

Mesh:

Year:  2014        PMID: 23836444     DOI: 10.1002/mus.23942

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  49 in total

Review 1.  Quality improvement in neurology: muscular dystrophy quality measures.

Authors:  Pushpa Narayanaswami; Richard Dubinsky; David Wang; Gina Gjorvad; William David; Jonathan Finder; Benn Smith; Jianguo Cheng; Frederic Shapiro; Michelle Mellion; Christopher Spurney; Jodi Wolff; John England
Journal:  Neurology       Date:  2015-09-08       Impact factor: 9.910

Review 2.  Intraspinal stem cell transplantation for amyotrophic lateral sclerosis.

Authors:  Kevin S Chen; Stacey A Sakowski; Eva L Feldman
Journal:  Ann Neurol       Date:  2016-02-12       Impact factor: 10.422

3.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

4.  Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy.

Authors:  Kenneth M Estrellas; Liam Chung; Lindsay A Cheu; Kaitlyn Sadtler; Shoumyo Majumdar; Jyothi Mula; Matthew T Wolf; Jennifer H Elisseeff; Kathryn R Wagner
Journal:  J Biol Chem       Date:  2018-08-23       Impact factor: 5.157

Review 5.  Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.

Authors:  Alan Moore; Carolyn A Young; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

6.  p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration.

Authors:  C Turnquist; I Horikawa; E Foran; E O Major; B Vojtesek; D P Lane; X Lu; B T Harris; C C Harris
Journal:  Cell Death Differ       Date:  2016-04-22       Impact factor: 15.828

7.  The economic burden of amyotrophic lateral sclerosis: a systematic review.

Authors:  K Achtert; L Kerkemeyer
Journal:  Eur J Health Econ       Date:  2021-06-18

8.  Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis.

Authors:  Ilene L Hollin; Holly L Peay; John F P Bridges
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

9.  Recording characteristics of electrical impedance-electromyography needle electrodes.

Authors:  H Kwon; J F Di Cristina; S B Rutkove; B Sanchez
Journal:  Physiol Meas       Date:  2018-05-22       Impact factor: 2.833

Review 10.  Genome engineering: a new approach to gene therapy for neuromuscular disorders.

Authors:  Christopher E Nelson; Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Nat Rev Neurol       Date:  2017-09-29       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.